Lin BioScience Inc.
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to eva… Read more
Lin BioScience Inc. (6696) - Net Assets
Latest net assets as of June 2025: NT$5.35 Billion TWD
Based on the latest financial reports, Lin BioScience Inc. (6696) has net assets worth NT$5.35 Billion TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$5.49 Billion) and total liabilities (NT$139.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$5.35 Billion |
| % of Total Assets | 97.45% |
| Annual Growth Rate | 106.39% |
| 5-Year Change | 488.34% |
| 10-Year Change | N/A |
| Growth Volatility | 206.62 |
Lin BioScience Inc. - Net Assets Trend (2019–2024)
This chart illustrates how Lin BioScience Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lin BioScience Inc. (2019–2024)
The table below shows the annual net assets of Lin BioScience Inc. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$5.35 Billion | +56.13% |
| 2023-12-31 | NT$3.43 Billion | +97.52% |
| 2022-12-31 | NT$1.74 Billion | +283.25% |
| 2021-12-31 | NT$452.98 Million | -50.22% |
| 2020-12-31 | NT$909.99 Million | +537.45% |
| 2019-12-31 | NT$142.75 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lin BioScience Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 233152300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$786.74 Million | 27.56% |
| Other Components | NT$4.97 Billion | 174.25% |
| Total Equity | NT$2.85 Billion | 100.00% |
Lin BioScience Inc. Competitors by Market Cap
The table below lists competitors of Lin BioScience Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Northwest Healthcare Properties REIT
PINK:NWHUF
|
$751.83 Million |
|
Chambal Fertilizers & Chemicals Limited
NSE:CHAMBLFERT
|
$752.16 Million |
|
TRUSTPILOT GROUP LS -01
F:6VZ
|
$752.28 Million |
|
Guangdong CHJ Industry Co Ltd
SHE:002345
|
$752.53 Million |
|
Maanshan Iron & Steel Company Limited
PINK:MAANF
|
$751.18 Million |
|
Core Laboratories NV
NYSE:CLB
|
$750.49 Million |
|
Jinzi Ham Co Ltd
SHE:002515
|
$749.68 Million |
|
Nagarro SE
PINK:NGRRF
|
$749.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lin BioScience Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,137,384,000 to 2,854,912,000, a change of 717,528,000 (33.6%).
- Net loss of 744,266,000 reduced equity.
- New share issuances of 98,379,000 increased equity.
- Other comprehensive income decreased equity by 37,342,000.
- Other factors increased equity by 1,400,757,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-744.27 Million | -26.07% |
| Share Issuances | NT$98.38 Million | +3.45% |
| Other Comprehensive Income | NT$-37.34 Million | -1.31% |
| Other Changes | NT$1.40 Billion | +49.06% |
| Total Change | NT$- | 33.57% |
Book Value vs Market Value Analysis
This analysis compares Lin BioScience Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.79x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 168.20x to 10.79x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$2.33 | NT$392.00 | x |
| 2020-12-31 | NT$14.36 | NT$392.00 | x |
| 2021-12-31 | NT$7.76 | NT$392.00 | x |
| 2022-12-31 | NT$17.20 | NT$392.00 | x |
| 2023-12-31 | NT$28.70 | NT$392.00 | x |
| 2024-12-31 | NT$36.32 | NT$392.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lin BioScience Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -26.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.94x
- Recent ROE (-26.07%) is above the historical average (-57.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -165.89% | 0.00% | 0.00x | 1.75x | NT$-249.44 Million |
| 2020 | -16.64% | 0.00% | 0.00x | 1.34x | NT$-243.08 Million |
| 2021 | -80.27% | 0.00% | 0.00x | 1.70x | NT$-488.86 Million |
| 2022 | -25.40% | 0.00% | 0.00x | 1.50x | NT$-436.94 Million |
| 2023 | -32.15% | 0.00% | 0.00x | 1.68x | NT$-900.93 Million |
| 2024 | -26.07% | 0.00% | 0.00x | 1.94x | NT$-1.03 Billion |
Industry Comparison
This section compares Lin BioScience Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lin BioScience Inc. (6696) | NT$5.35 Billion | -165.89% | 0.03x | $751.39 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |